JP2011525190A5 - - Google Patents

Download PDF

Info

Publication number
JP2011525190A5
JP2011525190A5 JP2011514829A JP2011514829A JP2011525190A5 JP 2011525190 A5 JP2011525190 A5 JP 2011525190A5 JP 2011514829 A JP2011514829 A JP 2011514829A JP 2011514829 A JP2011514829 A JP 2011514829A JP 2011525190 A5 JP2011525190 A5 JP 2011525190A5
Authority
JP
Japan
Prior art keywords
composition
peptide
seq
amino acids
different
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011514829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525190A (ja
JP5775451B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/047911 external-priority patent/WO2009155489A2/en
Publication of JP2011525190A publication Critical patent/JP2011525190A/ja
Publication of JP2011525190A5 publication Critical patent/JP2011525190A5/ja
Application granted granted Critical
Publication of JP5775451B2 publication Critical patent/JP5775451B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011514829A 2008-06-19 2009-06-19 インフルエンザを処置するための組成物および方法 Expired - Fee Related JP5775451B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
USPCT/US08/67471 2008-06-19
USPCT/US2008/067471 2008-06-19
US18261409P 2009-05-29 2009-05-29
US61/182,614 2009-05-29
PCT/US2009/047911 WO2009155489A2 (en) 2008-06-19 2009-06-19 Compositions and methods for treating influenza

Publications (3)

Publication Number Publication Date
JP2011525190A JP2011525190A (ja) 2011-09-15
JP2011525190A5 true JP2011525190A5 (enExample) 2012-08-02
JP5775451B2 JP5775451B2 (ja) 2015-09-09

Family

ID=41434704

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011514829A Expired - Fee Related JP5775451B2 (ja) 2008-06-19 2009-06-19 インフルエンザを処置するための組成物および方法

Country Status (9)

Country Link
US (1) US9603920B2 (enExample)
JP (1) JP5775451B2 (enExample)
KR (1) KR101701198B1 (enExample)
CN (1) CN102123724B (enExample)
AU (1) AU2009259964B2 (enExample)
BR (1) BRPI0914224A2 (enExample)
CA (1) CA2735724C (enExample)
IL (1) IL210097B (enExample)
WO (1) WO2009155489A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법
BR112012000826B1 (pt) 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
WO2012006367A2 (en) * 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
CA2890084C (en) 2011-11-18 2021-05-04 Maura Ellen Campbell Synthetic derivatives of mpl and uses thereof
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
WO2016194685A1 (ja) * 2015-06-02 2016-12-08 テルモ株式会社 アルミニウムを含有するアジュバント組成物およびこれを含むワクチン組成物
BR112019013402A2 (pt) 2016-12-28 2020-03-03 Invvax, Inc. Vacinas de influenza

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024241A (en) 1974-09-27 1977-05-17 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US3952097A (en) 1974-09-27 1976-04-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4349538A (en) 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4983387A (en) 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
US5939074A (en) 1986-12-30 1999-08-17 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptide antigens
EP0349579B1 (en) 1987-03-13 1992-01-08 Micro Vesicular Systems, Inc. Lipid vesicles formed of surfactants and steroids
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5817318A (en) 1989-05-03 1998-10-06 Connaught Laboratories Limited Synthetic peptides for an HIV-1 vaccine
DE3934366A1 (de) 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
DE4209215A1 (de) 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh Hcv peptidantigene und verfahren zur bestimmung von hcv
CA2081952A1 (en) * 1991-11-08 1993-05-09 John J. Donnelly Recombinant dna sequences and plasmids for cellular immunity vaccines from bacterial toxin-antigen conjugates, and methods of their use
GB9207731D0 (en) 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
GB9320597D0 (en) 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
ES2149340T3 (es) 1993-11-17 2000-11-01 Om Pharma Disacaridos de glucosamina, metodo para su preparacion, composicion farmaceutica que los comprende, y su uso.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5824506A (en) 1994-08-15 1998-10-20 Genelabs Diagnostics Pte. Ltd. Dengue virus peptides and methods
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
DE69733651T2 (de) 1996-07-03 2006-05-18 Eisai Co., Ltd. Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung
ZA975889B (en) 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
FR2760367B1 (fr) 1997-03-06 1999-04-30 Pasteur Merieux Serums Vacc Composition vaccinale destinee a la prevention ou au traitement des hepatites c
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
BR9809149A (pt) 1997-05-20 2000-08-01 Galenica Pharmaceuticals Inc Análogos de triterpeno saponina dotados de adjuvante e atividade imonoestimulatória
ATE365206T1 (de) 1998-02-13 2007-07-15 Adan Rios Verfahren zur entwicklung von einem hiv impfstoff
US6503753B1 (en) 1998-02-13 2003-01-07 Adan Rios Method for the development of an HIV vaccine
EP1078105B1 (en) 1998-05-12 2004-11-24 Genecure LLC Replication defective hiv vaccine
US7067134B1 (en) 1998-08-12 2006-06-27 University Of Western Ontario HIV vaccine
US7118874B2 (en) * 1998-10-09 2006-10-10 Variation Biotechnologies Inc. Immunogenic formulation and process for preparation thereof
GB9826069D0 (en) 1998-11-28 1999-01-20 Univ Leeds HIV vaccine
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
WO2001002607A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
EP1203088B1 (en) 1999-07-28 2005-03-30 Stephen Smith Conditionally controlled, attenuated hiv vaccine
FR2806912B1 (fr) 2000-04-04 2004-07-23 Fond Mondiale Rech Et Preventi UTILISATION DE PROTEINES gp120 ET gp160 MODIFIEES DANS LA BOUCLE V3 DU VIH-1 POUR LA PREPARATION DE COMPOSITIONS VACCINALES ET FORMULATIONS LES CONTENANT
EP1201750A1 (en) 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
CA2431500C (en) 2000-12-08 2016-06-07 Sjoerd Hendrikus Van Der Burg Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
ATE458496T1 (de) 2002-01-14 2010-03-15 Novartis Vaccines & Diagnostic Hiv-vakzine und anwendungsverfahren
CA2472265C (en) * 2002-02-08 2013-02-05 Variation Biotechnologies Inc. Immunogenic formulations of variable peptidic epitopes and process for preparation thereof
US20040180058A1 (en) * 2002-12-20 2004-09-16 Shneider Alexander M. Vaccine compositions and methods
US7566458B2 (en) * 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8080255B2 (en) * 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
JP5331340B2 (ja) * 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
CA2598884A1 (en) * 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
ATE552847T1 (de) 2005-03-01 2012-04-15 Variation Biotechnologies Inc Hiv-impfstoffzusammensetzung
CA2610667A1 (en) * 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation
US7348011B2 (en) 2005-06-10 2008-03-25 Sudershan Biotech Ltd. Hepatitis C virus vaccine
EP2097103B1 (en) 2006-11-30 2012-10-03 Variation Biotechnologies Inc. Influenza vaccine formulation
MX2009009530A (es) 2007-03-07 2010-05-19 Nventa Biopharmaceuticals Corp Composiciones de acidos nucleicos cerrados bicatenarios.
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
US7928190B2 (en) 2007-07-05 2011-04-19 Darnell Robert B Methods and compositions for tumor vaccination and therapy
EP2217064A4 (en) 2007-11-12 2012-10-03 Univ Pennsylvania NEW VACCINES FOR FIGHT AGAINST SEVERAL SUBTYPES OF INFLUENZA VIRUSES
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법

Similar Documents

Publication Publication Date Title
JP2011525190A5 (enExample)
JP7817257B2 (ja) ｍＲＮＡワクチンを送達するための脂質ナノ粒子
JP5764621B2 (ja) インフルエンザを阻害する組成物および方法
CN103096922B (zh) 用于治疗流行性感冒的组合物和方法
WO1994019013A1 (en) Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
HRP20190711T1 (hr) Imunogeni pripravak
JP2011512123A5 (enExample)
US12234263B2 (en) Influenza vaccines
RS67510B1 (sr) Optimizovana jedinjenja
JP2023527791A (ja) ウイルス性呼吸器感染症を治療するための方法
TW202430206A (zh) 組合疫苗
CN115243704B (zh) 肝脏和心血管病症的治疗
EP4687853A1 (en) Lipid nanoparticle compositions
JP2020515283A5 (enExample)
US20240366747A1 (en) Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs
JPH08506592A (ja) ３−ｏ−脱アシル化モノホスホリル脂質Ａ含有のインフルエンザワクチン組成物
WO2018084247A1 (ja) 免疫誘導剤
JP2015533821A5 (enExample)
JPWO2023057935A5 (enExample)
US20250049912A1 (en) Multicistronic Vaccine and Methods for Producing and Using the Same
JP6714260B2 (ja) インフルエンザウイルス感染阻害剤、リポソーム、インフルエンザ予防・治療剤
WO2023158158A1 (ko) 안지오텐신 전환효소 2를 포함하는 나노디스크 및 이의 항바이러스 용도
CN121712488A (zh) 非全身性mRNA施用